Table 4.
Effect of co-administration of dalcetrapib 900 mg with ezetimibe on changes in plasma lipids
| Dalcetrapib 900 mg alone | Dalcetrapib 900 mg + ezetimibe | Ezetimibe alone | |
|---|---|---|---|
| n | 25* | 27† | 22 |
| HDL-C, mean ± SD (mg dl−1) | |||
| Day 1 | 48.3 ± 11.1 | 48.2 ± 9.8 | 49.1 ± 9.7 |
| Final day of dosing | 62.7 ± 12.8 | 62.7 ± 10.7 | 46.7 ± 9.0 |
| Percent change | 25.6 | 29.8 | −4.8 |
| LDL-C, mean ± SD (mg dl−1) | |||
| Day 1 | 102 ± 27.5 | 106 ± 30.5 | 108 ± 21.3 |
| Final day of dosing | 87.7 ± 26.3 | 70.2 ± 25.4 | 86.2 ± 22.6 |
| Percent change | −16.1 | −35.9 | −20.9 |
| nonHDL-C : HDL-C ratio, mean ± SD | |||
| Day 1 | 2.5 ± 0.7 | 2.6 ± 0.7 | 2.5 ± 0.7 |
| Final day of dosing | 1.7 ± 0.5 | 1.4 ± 0.4 | 2.1 ± 0.5 |
| Percent change | −32.5 | −46.6 | −14.1 |
| Total cholesterol (mg dl−1), mean ± SD | |||
| Day 1 | 164 ± 29.3 | 167 ± 33.1 | 168 ± 25.4 |
| Final day of dosing | 164 ± 31.4 | 146 ± 28.4 | 145 ± 28.0 |
| Percent change | −1.24 | −13.1 | −14.3 |
| Triglyceride, mean ± SD (mg dl−1) | |||
| Day 1 | 80.4 ± 39.3 | 79.7 ± 35.4 | 66.0 ± 21.6 |
| Final day of dosing | 69.0 ± 30.4 | 65.0 ± 22.4 | 72.8 ± 33.1 |
| Percent change | −10.1 | −13.2 | 6.87 |
| VLDL-C, mean ± SD (mg dl−1) | |||
| Day 1 | 13.4 ± 6.9 | 13.2 ± 4.0 | 11.2 ± 4.1 |
| Final day of dosing | 13.5 ± 5.2 | 13.5 ± 3.7 | 11.9 ± 5.2 |
| Percent change | 8.9 | 6.1 | 1.8 |
*
n = 24 at day 7.
†
n = 26 at day 7.
Percent change was calculated from day 1 (pre-dose) to day 7 (post-dose).
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; VLDL-C, very low-density lipoprotein cholesterol.